Ken Griffin Erasca, Inc. Put Options Transaction History

Citadel Advisors LLC

8 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	SELL	$2.17 - $3.28 $83,979 - $126,935	-38,700 Reduced 44.95%	47,400 $129,000
Q2 2024 Aug 14, 2024	BUY	$1.79 - $2.63 $101,493 - $149,121	56,700 Added 192.86%	86,100 $203,000
Q1 2024 May 15, 2024	BUY	$1.67 - $2.55 $40,414 - $61,709	24,200 Added 465.38%	29,400 $60,000
Q4 2023 Feb 14, 2024	BUY	$1.67 - $2.49 $7,682 - $11,454	4,600 Added 766.67%	5,200 $11,000
Q3 2023 Nov 14, 2023	BUY	$1.97 - $2.91 $788 - $1,164	400 Added 200.0%	600 $1,000
Q2 2023 Aug 14, 2023	BUY	$2.57 - $3.3 $257 - $330	100 Added 100.0%	200 $0
Q1 2023 May 15, 2023	SELL	$2.74 - $4.44 $4,658 - $7,548	-1,700 Reduced 94.44%	100 $0
Q4 2022 Feb 14, 2023	BUY	$3.89 - $8.57 $7,002 - $15,426	1,800 New	1,800 $7,000

140

229M

28.7K

117K

Ticker ERAS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 122,147,000
Market Cap $310M
Description
Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...

Get notified when there are updates to the investment portfolio of Citadel Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Citadel Advisors LLC and Ken Griffin with notifications on news.